The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
 
Li-Tzong Chen
Honoraria - PharmaEngine
Consulting or Advisory Role - PharmaEngine
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Cell Therapeutics; Insys Therapeutics; McKesson; Medtronic
Honoraria - Celgene; Cerulean Pharma; Clarion Healthcare; Daiichi Sankyo; Genentech; Immunomedics; International Genomics Consortium; McKesson; Novartis; OncoMed; Peregrine Pharmaceuticals; Precision Medicine Research Associates, LLC; Puma Biotechnology
Consulting or Advisory Role - 3-V Biosciences; AgencyRx; Agenus; Aileron Therapeutics; Alethia Biotherapeutics; Alpha Cancer Technologies; Arsia Therapeutics; Arvinas; Azaya Therapeutics; Bellicum Pharmaceuticals; Biological Dynamics; Biomarin; Bionomics; Bristol-Myers Squibb; Buhl Oncology; CanBas; Caris Life Sciences; Cavion; Cerulean Pharma; CTI; CytRx Corporation; Daiichi Sankyo; dalian wanchun biotechnology; DNAtrix; Esperance Pharmaceuticals; Five Prime Therapeutics; Formula Pharmaceuticals; Halozyme; HealthCare Pharmaceuticals; Horizon Discovery; Ignyta; Imaging Endpoints; Immodulon Therapeutics; Immunomedics; Inform Genomics; Innate Pharma; Insys Therapeutics; Invivodata; Kinex; Lilly; Lixte Biotechnology; Lorus; MBC Pharma; Medelis; MediaPharma; Medical Prognosis Institute; Merus; miRNA Therapeutics; Momenta Pharmaceuticals; Nereus Pharmaceuticals; Novartis; Nucana; Oncology Venture; Oncolytics; Oncolyze; OncoMed; Pain Therapeutics; Peregrine Pharmaceuticals; Pharmacyclics; Pharmatech; Pledpharma; Precision Medicine Research Associates, LLC; Puma Biotechnology; RadioRx; Reflexion Medical; RenovoRx; Samsung; Samumed; Senhwa Biosciences; Superlab Far East; SynDevRx; TD2; Teva; Theravance; TNI Biotech; Tolero Pharmaceuticals; Toray Industries; Trovagene; Vaccinex; VidaCare
Research Funding - 3-V Biosciences (Inst); Abraxis BioScience (Inst); Agios (Inst); Bayer (Inst); Celgene (Inst); Eisai (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); Plexxikon (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
Travel, Accommodations, Expenses - Aileron Therapeutics; Bionomics; Caris Life Sciences; Celgene; Cell Therapeutics; Cerulean Pharma; Cylene; Daiichi Sankyo; DNAtrix; Five Prime Therapeutics; FORMA Therapeutics; Halozyme; Innate Pharma; Lilly; McKesson; Medical Prognosis Institute; miRNA Therapeutics; Novartis; Oncolytics; Partners Healthcare; Quintiles; RadioRx; Senhwa Biosciences; Vaccinex
 
Chung-Pin Li
No Relationships to Disclose
 
Andrea Wang-Gillam
Consulting or Advisory Role - Merrimack
Research Funding - Aduro Biotech (Inst); EMD Serono (Inst); Merrimack (Inst); Millennium (Inst); OncoMed (Inst); Pfizer (Inst); Prometheus (Inst)
 
Gyorgy Bodoky
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Lilly; Novartis; Roche
Speakers' Bureau - Amgen; Bayer; Lilly
 
Andrew Peter Dean
Honoraria - GlaxoSmithKline; Novartis
Consulting or Advisory Role - Specialised Therapeutics
 
Yan-Shen Shan
No Relationships to Disclose
 
Gayle S. Jameson
Speakers' Bureau - Celgene
 
Teresa Macarulla
No Relationships to Disclose
 
Kyung-Hun Lee
No Relationships to Disclose
 
David Cunningham
Research Funding - Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst)
 
Jean-Frédéric Blanc
No Relationships to Disclose
 
Richard Hubner
Honoraria - Celgene
Travel, Accommodations, Expenses - Lilly
 
Chang-Fang Chiu
No Relationships to Disclose
 
Gilberto Schwartsmann
No Relationships to Disclose
 
Jens T Siveke
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Merrimack
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Novartis (Inst)
 
Fadi S. Braiteh
Stock and Other Ownership Interests - Celgene; Insys Therapeutics
Honoraria - Amgen; BIND Therapeutics; Caris Life Sciences; Dendreon; Foundation Medicine; Incyte; Insys Therapeutics; MolecularHealth; Novartis; Pfizer; Saladax Biomedical; Sanofi
Consulting or Advisory Role - Amgen; BIND Therapeutics; Caris Life Sciences; Dendreon; Foundation Medicine; Incyte; Insys Therapeutics; MolecularHealth; Novartis; Pfizer; Saladax Biomedical; Sanofi
Speakers' Bureau - Amgen; Bayer; Bristol-Myers Squibb; Caris Life Sciences; Celgene; Genomic Health; Incyte; Insys Therapeutics; Myriad Pharmaceuticals; Novartis; Pfizer; Sanofi
Research Funding - Abbvie; Active Biotech; Amgen; AstraZeneca/MedImmune; Bayer; BIND Therapeutics; Biomarin; bioTheranostics; BN ImmunoTherapeutics; Boston Biomedical; Bristol-Myers Squibb; Caris Life Sciences; Celgene; Cell Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Exelixis; Foundation Medicine; Genomic Health; Gilead Sciences; GlaxoSmithKline; Halozyme; HERON; ImClone Systems; Incyte; Insys Therapeutics; Janssen; Lilly; MEI Pharma; Merrimack; Millennium; MolecularHealth; Novartis; Pfizer; Pharmacyclics; Plexxikon; PSMA Development Company; Roche/Genentech; Saladax Biomedical; Sanofi; Seagen; Viamet Pharmaceuticals
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Caris Life Sciences; Celgene; Foundation Medicine; Genomic Health; Gilead Sciences; HERON; Incyte; Insys Therapeutics; Lilly; MolecularHealth; Pfizer; Roche/Genentech; Saladax Biomedical; Sanofi
 
Victor M. Moyo
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
 
Bruce Belanger
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
 
Eliel Bayever
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
Patents, Royalties, Other Intellectual Property - Merrimack